Healthcare

Viridian Therapeutics is developing new treatments for thyroid eye disease, aiming to improve convenience in a market that already has proven demand. Its focused pipeline and late-stage progress make it a name worth deeper analysis for long-term biotech watchers.

Vera Therapeutics is focused on atacicept for serious immune-mediated kidney diseases, especially IgA nephropathy. The company operates in a growing treatment area, and its future profile could change sharply if late-stage development continues to advance.

Vericel sells advanced therapies for cartilage repair and severe burns, with MACI driving most revenue. Growth has remained strong, cash flow has improved, and profitability has turned positive, making the company notable for its progress from niche biotech to scaled commercial operator.

UFP Technologies makes specialized medical components, single-use products, and protective packaging. The company has paired rapid revenue growth with strong margins and rising cash flow, making its niche healthcare position worth a closer look.